Clinical Trial Update: Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a tumor antigen-loaded dendritic cell-derived exosome vaccine for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tumor antigen-loaded dendritic cell-derived exosome vaccine

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED